Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the first quarter 2024 and provided a business update.
- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the first quarter 2024 and provided a business update.
- Granted U.S. patent covering use of Trappsol® Cyclo™ for treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office.
- Net loss for the quarter ended March 31, 2024 was approximately $4.3 million.
- Research and development expenses decreased 16% to $2.8 million for the quarter ended March 31, 2024, from $3.4 million for the quarter ended March 31, 2023.